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CUMMINGS, B. J., T. SATOU, E. HEAD, N. W. MILGRAM, G. M. COLE, M. J. SAVAGE, M. B. PODLISNY, D. J. SELKOE, R. 
SIMAN, B. D. GREENBERG AND C. W. COTMAN. Diffuse  plaques contain C-terminal  A~42 and not A~4o." Evidence  from cats and 
dogs. NEUROBIOL AGING 17(4) 653-659,  1996.--Recent reports have suggested that 13-amyloid  (A[3) species of variable length 
C-termini are differentially deposited within early and late-stage plaques and the cerebrovasculature. Specifically, longer C-terminal 
length A~42/3 fragments (i.e., AI3 forms extending to residues 42 and/or 43) are thought to be predominant within diffuse plaques while 
both A~42/3 and AI34o  (AI3 forms terminating at residue 40) are present within a subset of neuritic plaques and cerebrovascular deposits. 
We sought to clarify the issue of differential A~ deposition using aged canines, a partial animal model of Alzheimer's disease that 
exhibits extensive diffuse plaques and frequent vascular amyloid, but does not contain neuritic plaques or neurofibrillary tangles. We 
examined the brains of 20 aged canines, 3 aged felines, and 17 humans for the presence of AI3 immunoreactive plaques, using 
antibodies to A~I_lT, A~17_24, A~1_28, A~40, and AI342. We report that plaques within the canine and feline brain are immunopositive 
for A~42 but not A~;4o. This is the first observation of nascent AD pathology in the aged feline brain. Canine plaques also contained 
epitopes within A~l._lT,  A[~17_24,  and AI31_28. In all species examined, vascular deposits were immunopositive for both A~4  o and A~42. 
In the human brain, diffuse plaques were preferentially A~42 immunopositive, while neuritic plaques and vascular deposits were both 
A~4  o and AI342  immunopositive. However, not all neuritic plaques contain A~4  o epitopes. 
Amyloid  C-terminal epitope  Senile plaque development  Alzheimer's disease 
Amyloid angiopathy  Canine  Feline 
Animal models of aging 
SENILE plaques have long been considered the hallmark lesion of 
Alzheimer's disease (AD); however, only in the last decade have 
scientists appreciated that [A] the major constituent of plaques is 
an --4 kD peptide, 42 to 43 amino acids in length, termed 13-amy- 
loid (A~) (11,22); and [B] lhat senile plaques exhibit heterogeneity 
in terms of AI3 peptide length, AI3 conformation, and morphology. 
Plaques are subtyped into three categories based on morphology, 
13-sheet conformation and the  association of additional reactive 
elements (i.e., dystrophic neurites, astrocytes,  and microglia) (6, 
44).  These subtypes are generally referred to  as diffuse (nonq3- 
sheet), primitive (13-sheet lacking a  central core of amyloid and 
containing few  dystrophic neurites or reactive glia), or neuritic 
(13-sheet with a central core of amyloid and containing extensive 
dystrophic neurites and reactive glia). 
Further complicating our understanding of plaque formation, 
the C-terminus of plaque A[3 can range from amino acid position 
39 to greater than 42 [for review, see (13,34)]. There is evidence 
of N-terminai heterogeneity as well (23,31). A  number of recent 
studies have suggested that AI3  within mature, neuritic plaques 
consists of both AI34o and AI3~:, while AI3 within diffuse plaques 
is predominantly A~42 (12,15,21,24,32,37,45,47). However, stud- 
ies that address this question by protein isolation and extraction 
1 Since the acceptance of this article, two additional reports (48,49) have been published confirming the predominance of AI342  C-terminal species within 
the aged canine brain using immunocytochemistry and/or protein extraction, purification, and HPLC. 
2 To whom correspondence should be addressed, Dr. Brian Cummings, Laboratories for Molecular Neurosciences, Mailman Research Center, McLean 
Hospital, 115 Mill Street, Belmont, MA 02178. cummings@helix.mgh.harvard.edu 
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from tissue risk losing specific peptide species due to differing 
solubilities or contamination from vascular deposits of amyloid. 
Numerous studies have demonstrated that the aged canine ex- 
hibits early AD pathology (9,33,39), but the A[3 immunoreactive 
plaques within the canine brain are nearly always thioflavine or 
Congo red negative and lack dystrophic neurites and neurofibril- 
lary tangles (NFTs)  [for review,  see (8)].  Thus,  we chose  this 
animal model to address whether diffuse plaques contain A134o, 
A~42 or both. We also tested three aged cats. Finally, we examined 
mild, moderate, and severely demented AD patients and nonde- 
mented  controls  for  the  presence  of  AI34o  and  A[342- 
immunopositive plaques. We used antibodies that specifically  rec- 
ognize either A[34o or A[342. We would predict that the diffuse 
plaques within the dog and cat brain are AI342 positive and A[34o 
negative, while progressively more plaques are A[34o positive as 
the severity of AD related dementia increases. 
METHOD 
Twenty aged canines and three aged felines were examined. 
Dogs, ranging in age from 9 to 18 years, were obtained from the 
Inhalation and Toxicology Research Institute (Albuquerque, NM). 
The three cats were family pets, 15, 16, and 20 years of age; they 
were euthanized for age-related medical problems. Human tissue 
(n  =  17)  was  obtained from the  Brain  Aging Institute Tissue 
Repository (U.C. Irvine). AD cases met CERAD neuropathologi- 
cal and clinical criteria for AD. Human cases were selected based 
on level of cognitive impairment as assessed by the MMSE and the 
extent of neuritic dystrophy (28). Four nondemented controls, five 
mild, four moderate, and four late-stage cases were used to exam- 
ine progressive changes with increasing disease severity. The av- 
erage age was 78, and the average postmortem delay was 4.7 h. All 
tissue (with the exception of the 20-year-old cat) was immersion 
fixed in 4.0% paraformaldehyde, transferred to phosphate buffered 
saline with 0.02%  sodium azide, pH 7.4, and stored at 4°C. The 
oldest cat was  fixed in  5%  formalin for 2  h  and embedded in 
paraffin. 
Cases were prescreened for the presence of 13-amyloid using a 
rabbit polyclonal antibody (anti-A[3,  previously called "1342"), 
raised against synthetic AI31~  2 peptide (46) While this antibody 
does not differentiate between AI3~_4o and AI31_42, it is highly 
sensitive and exhibits minimal background crossreactivity. Cases 
were then tested with anti-70 (1:700 dilution) and anti-74 antibod- 
ies (1:1000 dilution) (Cephalon, Inc., PA) (32),  and anti-34-40 
(1:1000 dilution) and anti-2G9 (1:1500)  (G. Cole, VA Hospital, 
Sepulveda) (21,47).  These antibodies selectively differentiate be- 
tween the C-termini of A134o (anti-70 and anti-34-40) and A[342 
(anti-74 and anti-2G9) (see below). Cases were also tested with 
antibodies against A[31_17 (anti-6E10;  H.  Wisniewski), A[317_24 
(anti-4G8; H. Wisniewski) (20), and AI31_2s (anti-1328; B. Cum- 
mings). 
The four C-terminal antibodies have been previously demon- 
strated to  distinguish exclusively either AI34o or AI342, respec- 
tively, on Western blots and dot blots and can be preadsorbed only 
by  their respective antigen  but  not  by  the  alternate length  C- 
terminal peptide (21,32,47).  Anti-2G9 specificity was also verified 
by sandwich ELISA and following in vivo injection of both AI3~_ 
40 and AI3~_42 peptides into rodent brain,  where anti-2G9 only 
detects AI31-42 deposits (47). The selectivity of anti-70 and anti-74 
was determined by competitive ELISA, where 0.1  p,g/mi of AI31_ 
4o peptide effectively bound anti-70, while even 100x greater con- 
centration of A131~  2 peptide had no effect. Conversely, 0.1 ixg/ml 
of AI3~,  2 peptide effectively bound  anti-74,  while  100x  more 
AI31_4o or AI31._4s peptides were needed to bind the same amount 
of anti-74 (32). 
Vibratome sections (50  Ixm) of dorsal lateral frontal cortex, 
entorhinal cortex, and hippocampus were incubated overnight in 
various A[3  antibodies following 4  min  in 70%  formic acid as 
previously described (10).  Sagittal sections of the 20-year-old cat 
were cut at 6 Ixm and processed while mounted on slides. Adjacent 
sections from all cases were stained with thioflavine and Congo 
red to verify the presence of "diffuse only" cases, and to identify 
plaques with a [3-sheet conformation in the more severely affected 
human cases. In addition to standard immunohistochemical con- 
trois (e.g., omission of primary antibody, use of incorrect second- 
ary  species), the  specificity of the  antibodies  was  verified by 
preadsorption with 30 ixg/ml of either synthetic A[31~,o or A[31_42 
peptide. 
RESULTS 
Staining with  both  anti-A[334_4o and  anti-70  antibodies was 
similar; for brevity, we refer to these antibodies collectively as 
AI34o antibodies unless otherwise noted. Anti-2G9 and anti-74 are 
collectively referred to  as A1342 antibodies. Immunostaining by 
both anti-A[34o antibodies was blocked by the addition of A~l_4O 
but not not AI31_42 peptides. Conversely, anti-A~42 staining was 
blocked by A[31_42 but not AI31~  o peptides, indicating that these 
antibodies selectively differentiate between AI3 ending in residue 
40 vs. 42 in situ. 
Dog Brain 
Prescreening with our polyclonal AI3 antibody (which does not 
differentiate between AI34o and AI342  )  revealed the presence of 
numerous diffuse plaques within all of the dog brains selected. No 
thioflavine or Congo red positive plaques were detected. As re- 
ported previously (9),  a  diffuse cloud of AI3 was  occasionally 
observed (n =  5) spanning the length of the molecular layer of the 
dentate gyms. Antibodies directed against N-terminal domains of 
AI3 also revealed plaques within the dog brain (A[31_17  , A[317_24  , 
and AI31_2s  ). 
Using antibodies against the  free C-terminus  of AI3, canine 
plaques were clearly AI342 positive (Fig. 1B). Except for slightly 
higher background, the staining pattern using both AI342 antibodies 
was indistinguishable from that reported previously (9). Large and 
small plaques, some neurons, and vessel-associated amyloid were 
detected with both A[342 antibodies. In some dogs, vascular amy- 
loid was more immunoreactive with A[342 antibodies in compari- 
son to A134o antibodies, in others, AI34o  staining was stronger (Fig. 
1D and E). Cellular processes as well as discrete fibers within the 
neuropil and  associated with  plaques  were  detected containing 
A[342 epitopes. The laminar zone of AI3 within the molecular layer 
of the  dentate gyrus was also A~42  immunopositive (Fig.  1C). 
Interestingly, antibodies to A[317_24 (anti-4G8) often labeled intra- 
neuronal granular structures that appeared to be lysosomes based 
on morphology and autofluorescence (Fig. IF). Similar structures 
were also detected with A[342 antibodies as well. However, further 
studies will be necessary to confirm the nature of this staining (i.e., 
AI3 or C-terminal APP fragments), because antibody 4G8 cross- 
reacts with a 31 kD C-terminal fragment of APP (20). 
In contrast to these findings, very different immunoreaetivity 
was observed with A[34o antibodies. Even at concentrations that 
clearly detected plaques within the human brain (see below), A~4  o 
antibodies failed to label dog plaques.  The cytoplasm in many 
neurons, particularly pyramidal neurons, was faintly to moderately 
A[34o immunoreactive. A[3ao antibodies also labeled the basement 
membrane of capillaries  in dogs with amyloid angiopathy (see Fig. 
1A).  Conversely, the laminar zone of AI3 deposition within the 
dentate gyrus was not AI34o immunopositive (not shown).  Both 
AI34o antibodies yielded qualitatively similar results; however, 
anti-34--40 stained neurons slightly more intensely than did anti- 
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FIG.  1. Demonstration  of [3-amyloid deposition within the aged canine and feline brain with antibodies against AI34o and A~42 
epitopes. (A) PlacLues within neighboring  sections of dorsal lateral frontal cortex of this  14-year-old dog were negative for A[~4o 
while in B, numerous A1342 immunopositive plaques were detected (arrows). Faint vascular staining was detected with antibodies 
to both A[~4o and A[342 (arrowheads).  (C) In five dogs, a laminar zone of AI3 deposition within the dentate gyrus molecular layer 
could be seen with A~42 antibodies (arrows) but not with AI34o  antibodies (not shown). Vascular amyloid deposition was frequently 
detected  with  both  A134o and  A1342 antibodies  (D  and  E).  In addition  to the  detection  of plaques,  anti-4G8  revealed  dense 
accumulations of AI3 (or APP) within some neurons in entorhinal cortex, which appeared similar to the lysosomal accumulation of 
APP reported in the human brain [see (4,5)] (arrows) (F). In a 16-year-old cat, faint neuronal staining was detected within entorhinal 
cortex with A[~4o antibodies (G), while in H, several diffuse plaques were detected with A[~42 antibodies (arrows). Scale bar equals 
200 I~m for A, B, C, G, and H; 100 p.m for D, E, and F. o, m, i, and gc refer to outer, middle, and inner molecular layer and granule 
cell layer, respectively. 
Cat Brain 
According to their owners, each of the cats studied exhibited 
abnormal behavior within the final years of life, including wan- 
dering,  "confusion"  and  night time howling.  The oldest cat,  in 
particular,  was  described  as  exhibiting behavior  "suggestive of 
Alzheimer's disease."  Neuropathologically, the 20- and  16-year- 
old  cats  contained  exten~,;ive AJ3  deposition  using  our  anti-AI3 
("1342") antibody. Fewer plaques were present within the 15-year- 
old  cat.  These  plaques  were  neither  thioflavine nor  Congo  red 
positive, nor did they contain dystrophic neurites or neurofibrillary 
tangles detectable with antibodies against paired helical filaments 
(PHF-1), AT8, or tan (not shown). Cat plaques were often unusu- 
ally large, and  in some fields,  spanned  the entire cortical depth, 
particularly  in  the  15-  and  16-year-old  cats.  In  the  oldest  cat, 
plaques were more intensely labeled and denser (not shown). Nu- 
merous  neurons  were visible within the cortex occupied by  A[3 
deposition. Neurons were weakly A[34o immunopositive. A~42 im- 
munopositive fibers and neurons were also present. Although im- 
possible to determine based on just three cats, it appears as if the 
neuronal accumulation of A~ immunoreactivity may be as exten- 
sive as that observed in the dog. Like plaques within the dog brain, 
cat plaques were positive for A~42, but negative for A~4  o. Vessel- 
associated AI3 was weakly detected with both the A134o and A~42 
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Human Brain 
Numerous  anti-A[3  ("1342")-immunopositive  plaques  were 
present within all AD cases.  Sufficient numbers of plaques were 
also present within the nondemented controls to permit a determi- 
nation of whether these plaques were predominantly AI34o or A[342 
immunopositive.  Thioflavine  and  Congo  red  failed  to  detect 
plaques in neighboring sections from these control brains. 
Using C-terminus-specific AI3 antibodies, AI3n2 immunoposi- 
tive plaques were present in every case. As reported previously in 
a different set of cases (7), the extent of A1~42 deposition increased 
in relation to clinical disease severity. In the most demented cases, 
the majority of cortex was  occupied by AI3~2 deposition•  A[3no- 
immunopositive plaques were present in the moderate and severely 
demented cases, but never in numbers equal to those detected with 
A1342 antibodies (Fig. 2A-D). Plaques within the nondemented and 
mild AD groups were A~42 positive but A[~4o negative (Fig. 2E 
and F).  Vascular deposits of A[3 were frequently both A~4  o and 
A13~2 immunopositive, with a tendency for greater A~4  o labeling 
compared to A[342 (32). As in dog tissue, both A[~4o antibodies and 
both A[~42 antibodies yielded similar results. 
Interestingly, antibodies to A~4  o labeled the cytoplasm of more 
neurons than A[~42. This may be the result of greater background 
staining with m[~40 antibodies; however, A[340 antibodies require a 
free C-terminus and are less likely to detect other metabolites than 
other antibodies. A[~40 antibodies detected numerous intracellular 
and  extracellular NFTs  and  dystrophic  neurites  (Fig.  2C).  Con- 
versely,  A[~42 antibodies  primarily  labeled  extracellular  NFTs 
.  .  •  -,  ¢,.;..  ,¢ 
E?  -.A  '  "  ~. 
,~  .  ~'.  . 
FIG. 2. Demonstration of A[34o and A[~42  C-termini-labeled plaques within demented and nondemented humans. Antibodies to AI34o 
(A) and AI342 (B) labeled a row of plaques within the molecular layer of the dentate gyrus in this late-stage AD case (Age 88, MMSE 
=  1). Vessel-associated  staining was detected with both A[34o and A[342 antibodies (arrowheads). In a moderately demented AD 
case (Age 91, MMSE =  12), antibodies to AI34o (C) revealed NFTs (white arrows), vascular deposition (arrowheads) and a few 
plaques (black arrow) while, antibodies to A~42 (D) detected numerous plaques (arrows) and faint vascular staining (arrowheads). 
In a nondemented control case (Age 81) (E), antibodies to AI34o still reveal faint vascular AI3 (arrowheads), but no NFTs or plaques. 
(F) Antibodies to A1~42, however, demonstrate the presence of faint, diffuse plaques (arrows). Scale bar equals 200 ixm in A-F. C-TERMINAL  EPITOPES  AI3  IN  EARLY  PLAQUES  657 
(27). Interestingly, AI34o-immunopositive  NFTs were often present 
in mild and moderate cases of AD that lacked A~40 plaques. Only 
in  the more  severe cases  of AD  were both NFTs  and plaques 
detected with AI34o antibodies. 
DISCUSSION 
We report several findings. First, diffuse plaques and the lami- 
nar zone of AI3 deposition within the dentate gyms in the aged dog 
brain are immunoreactive with C-terminal antibodies against AI342 
but not A~40. Second, diffuse plaques and neuronal accumulation 
of AI3 are also present within the aged cat brain. Cat plaques were 
also  immunoreactive for  l~k~4  2  and  not  AI34o. Further,  neuritic 
plaques within the human AD brain contain primarily AI342 and 
occasionally A~4o; diffuse plaques within nondemented controls 
and mild AD cases were detected with AI342 antibodies but not 
with A~4  o antibodies. Ve:~sel-associated AI3 was  detected with 
both AI342 and A~4  o antibodies in humans, dogs, and cats. Based 
on the progression of changes in nondemented and mild cases to 
moderate and severely demented cases, it appears that plaques are 
initially AI342 positive, then greater levels of A~40 and A~42 ac- 
cumulate  within  neurons  and  NFFs. Finally, in  late-stage AD, 
some plaques are found to be both AI342 and A~4  o positive, while 
many remain exclusively tk~42 immunopositive. 
Several recent studies have  suggested that A[3 found within 
diffuse  plaques  is  predo:aainantly A~42, while  neuritic  stage 
plaques contain A~40 epitopes as well (15,37,45).  Using an animal 
model of plaque formation which is essentially "arrested" in the 
diffuse plaque stage, we faund that early plaques contain exclu- 
sively AI342, Unlike in the rodent, the amino acid sequence of AI3 
in  the  dog,  deduced from  amplified cDNA,  is  identical to  the 
human  (19).  Immunohis~;ochemically, antibodies  to  epitopes 
within A~l_17, A~17_24  , A~1_28 and C-terminal AI342 all detected 
AI3 within dog plaques. In contrast, antibodies to AI34o failed to 
label plaques in the dog or cat. This is consistent with the presence 
of diffuse only plaques in dog and cat, and with observations in 
human brain. We are aware of only one other study investigating 
AD-like pathology in the  aged cat brain,  where  silver staining 
failed to detect plaques or tangles (2).  It is possible that more 
sensitive immunohistoche:aaistry techniques  for AB  would have 
detected plaques in cat brain, because Braak et al. also did not 
observe silver positive pleLques within dog brain. However, their 
results support the classification of cat plaques as "diffuse." Had 
we not used formic acid ptetreatment in the present study, plaques 
within the cat brain woulcL not have been detected. 
Many studies have deraonstrated that AI342 has a greater pro- 
pensity for self-aggregation than shorter fragments (3,17).  In neu- 
roblastoma cells transfected to overexpress APP, the majority of 
AI3 produced is AI3~_4o (36). The more insoluble A~42 fragments 
may accumulate within the neuropil. A~42 may also act as a seed 
for the further collection of AI3 and the later accumulation of other 
species such as AI34o (16,17,38). It is possible A~4  o does not have 
sufficient time to accumulate within dog or cat tissue or that plaque 
maturation involves the participation of additional components or 
cells (e.g., heparan sulfate proteoglycans or microglia). Alterna- 
tively, different processinlg  mechanisms or chaperones may pref- 
erentially deposit A~42 as the initial event in AI3 accumulation. A 
third possibility is that AI34o is primarily intraneuronal and does 
not get deposited in the extracellular space until late in the disease. 
The fact that cultured primary human fetal neurons constitutively 
secrete large amounts of A[3 would argue against this latter pos- 
sibility (14).  The presence., of intracellular NFF staining for AI3 is 
interesting because AI3 is allegedly produced in a secretory path- 
way. However, AI3 can be taken up by cells in vitro, where it enters 
lysosomes (46).  It has been suggested that alterations within the 
endosomal-lysosomal system are some of the earliest pathologies 
to be observed in the progression of AD (4,5).  Several other pro- 
teins that should also be extracellular (e.g., heparan sulfate pro- 
teoglycans, apolipoprotein E) are also taken up by the endosomal 
lysosomal system and have been found to label NFTs (1,35), sug- 
gesting a possible interaction between the lysosomal system and 
NTTs, which may be involved in an attempt to degrade NFTs, AI3 
or their precursors. 
We found that plaques present within the AD brain were AI342 
positive, while only a subset were AI34o  positive, even in late-stage 
AD cases. Because the majority of plaques within end-stage AD 
are neuritic, the relative ratio of AI342- vs. AI34o-positive plaques 
present within end-stage AD indicates that many neuritic plaques 
do not contain A~4  o. This conclusion is supported by both A~42 
antibodies, although it is possible the sensitivity of A~42 antibod- 
ies exceeds that of AI34o antibodies. However, anti-70 is signifi- 
cantly more sensitive than anti-74 at detecting its respective anti- 
gen at the titers used in this study (32).  Further, both A~40 anti- 
bodies strongly labeled NFTs, and this reaction could be blocked 
by the addition of A[31_~o peptide to the antibody solution. Thus, 
it is likely that many neuritic plaques simply do not contain sig- 
nificant levels of AI34o epitopes compared to A~42 epitopes. 
Interestingly, some studies have suggested that vascular amy- 
loid consists predominantly of m~39 (29) or A~4  o (18), and not 
A[342 (24),  while  others  indicate that both  A[34o and A~42  are 
present within vascular amyloid deposits (30,32,45,47).  In man, 
we found both forms of AI3 were present within vessels and vas- 
cular deposits. In the  aged dog, which often exhibits extensive 
amyloid angiopathy (9,33,40),  vascular A[3  was  predominantly 
A~42 immunopositive, although vessels were also labeled by AI34o 
antibodies. While the relative staining intensities were often simi- 
lar for A~40 vs. A~42, it appeared that AI34o antibodies labeled 
more vascular deposits, on average, than A[342 antibodies. 
Aged canines  parallel very closely the  initial stages of AI3 
deposition and plaque formation in man. This initial AB deposition 
in  dogs  and cats is nonfibrillar and thioflavine negative. Thus, 
plaque development appears to be "arrested" at the diffuse stage 
in this animal model (8). Further evidence that diffuse plaques are 
an initial stage comes from the progression of diffuse AI3 to thio- 
flavine positive AI3 with age in Down's syndrome (43). We have 
suggested  that  the  presence  of  intact  neurons  within  canine 
plaques,  coupled  with  intraneuronal  accumulation  of AI3,  are 
strong evidence for the neuronal origin of plaques and the depo- 
sition of AI3 (9). This is in accordance with data from other groups 
who also suggest that plaques are neuronal in origin (39,41).  Sup- 
porting morphological evidence is  that  the  density gradient of 
plaque AI3 within the human brain radiates outward as if from a 
neuronal source (25,26). Why canine and feline plaques remain in 
a diffuse state is another question. It has been suggested that both 
astrocytes and microglia play an important role in plaque forma- 
tion (28,42). We have previously demonstrated that canine plaques 
do not contain extensive reactive astrocytes or microglia (9). Per- 
haps these additional cell types are involved in the maturation of 
diffuse plaques to neuritic plaques in the human brain. Or APP and 
AI3 fragments may be processed intracellularly via different endo- 
somal-lysosomal pathways in humans than in shorter lived ani- 
mals. Alternatively, additional plaque components that modulate 
their neuritic maturation may be lacking in nonhuman  plaques, 
such as heparan sulfate proteoglycans or apolipoprotein E. 
Information about the relative abundance of AI34o vs. AI342, as 
well as which species is initially deposited, will be critical to the 
development of therapeutic approaches to AI3 accumulation (13). 
Further, we must determine the source of AI3 within plaques and 
vascular deposits in  the  aged brain.  In our opinion, the  initial 
similarities but subsequent cessation of pathologic progression in 
the canine (and possibly the aged feline) are very important for two 658  CUMMINGS  ET  AL. 
reasons: [A] the aged canine is an excellent model to test agents/ 
therapeutics aimed at slowing or reducing AI3 deposition, [B] Be- 
cause even very old dogs  exhibit only diffuse plaques,  one can 
study the potential differences between canine and man that un- 
derlie  the progression  of plaque  development or the processing 
of AI3. 
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